Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Durvalumab + Oleclumab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 89 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov). |
| Oleclumab | MEDI9447 | Adenosine Targeting 19 CD73 Antibody 10 | Oleclumab (MEDI9447) is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 27622077). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03794544 | Phase II | Durvalumab + Oleclumab AZD9150 + Durvalumab Durvalumab Durvalumab + Monalizumab | Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | Completed | USA | ITA | FRA | ESP | CAN | 2 |
| NCT04262388 | Phase II | Durvalumab + Oleclumab | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) | Withdrawn | CAN | 0 |
| NCT03833440 | Phase II | Ceralasertib + Durvalumab Durvalumab + Oleclumab Docetaxel Durvalumab + Monalizumab | Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR) | Recruiting | FRA | 0 |
| NCT03822351 | Phase II | Durvalumab Durvalumab + Monalizumab Durvalumab + Oleclumab | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | 4 |
| NCT04262375 | Phase II | Durvalumab + Oleclumab | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION) | Withdrawn | CAN | 0 |
| NCT04668300 | Phase II | Durvalumab + Oleclumab | Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa) | Recruiting | USA | 0 |
| NCT03819465 | Phase I | Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel AZD9150 + Durvalumab Cisplatin Durvalumab | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) | Active, not recruiting | USA | ESP | CAN | BEL | AUT | 5 |
| NCT05061550 | Phase II | Durvalumab + Monalizumab Durvalumab + Oleclumab | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) | Recruiting | USA | ITA | FRA | ESP | CAN | 2 |
| NCT03773666 | Phase I | Durvalumab + Oleclumab Durvalumab | A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) | Active, not recruiting | USA | 0 |
| NCT05221840 | Phase III | Durvalumab + Oleclumab Durvalumab Durvalumab + Monalizumab | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 15 |
| NCT03875573 | Phase II | Durvalumab Durvalumab + Oleclumab | Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay) | Recruiting | FRA | BEL | 0 |
CKB BOOST